Table 2.

VE (ATP) against 1-year persistence with HPV16 stratified by HPV16 and HPV18 serology at enrollment

HPV serologyabArmWomen, NWomen with events, nRate per 100 women95% CIRate reduction per 100 women95% CIVE, %95% CI
HPV16 serology negativeVaccine
Control
1,875
1,856
4
51
0.2
2.7
0.1–0.5
2.1–3.6
2.52.0–2.892.280.3–97.6
HPV16 serology positiveVaccine
Control
558
551
4
8
0.7
1.5
0.2–1.7
0.7–2.7
0.7−0.5 to 1.750.6−63.3 to 87.0
HPV18 serology negativeVaccine
Control
1,853
1,854
4
44
0.2
2.4
0.1–0.5
1.8–3.1
2.21.6–2.490.976.7–97.2
HPV18 serology positiveVaccine
Control
563
541
3
14
0.5
2.6
0.1–1.4
1.5–4.2
2.10.6–2.979.433.5–95.3
  • a The stratification by HPV16 serology excludes 31 and 45 subjects without HPV16 serology results from the vaccine and control arm, respectively.

  • b The stratification by HPV18 serology excludes 48 and 57 subjects without HPV18 serology from the vaccine and control arm, respectively.